Proteomic Pattern Recognition Technology to Help Identify and Characterize Potential Resistance Patterns in Recruited Patients, Provide Correlative Biomarkers to Guide Outcomes
Read more at prnewswire.comOncoHost's PROphet® Platform to Support Henlius US-Based Phase III Trial for Patients with Extensive-Stage Small Cell Lung Cancer
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here